Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 19, Issue 2, Pages 275-283Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543780903501539
Keywords
fibrosis; glomerulosclerosis; inflammation; proteinuria; renal failure
Categories
Funding
- Intramural NIH HHS [Z99 DK999999] Funding Source: Medline
Ask authors/readers for more resources
Importance of the field. Many chronic diseases of various etiologies lead to fibrosis and organ dysfunction. Despite many advances in medicine in recent years, options to slow the progression of fibrotic diseases have remained limited. The recent availability of pirfenidone, an antifibrotic and anti-inflammatory investigational agent, thus offers a new hope for treating progressive fibrotic diseases. Areas covered in this review. This review provides concise review of the available data regarding the mechanism and pharmacokinetics of pirfenidone and preclinical and clinical data regarding efficacy and safety in fibrotic diseases of the kidney. It also reviews results of clinical trials involving pirfenidone in other fibrotic diseases. What the reader will gain: The review will provide in-depth review of pirfenidone with a renal focus. Take home message: Because many of the available clinical trials have been small and/or uncontrolled, conclusive evidence regarding efficacy and safety of pirfenidone is lacking, particularly in patients with renal or hepatic dysfunction. Larger studies are needed to better understand long-term efficacy and safety of this medication in various patient populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available